1
|
Onida F, Sbianchi G, Radujkovic A, Sockel K, Kröger N, Sierra J, Socié G, Cornelissen J, Poiré X, Raida L, Bourhis JH, Finke J, Passweg J, Salmenniemi U, Schouten HC, Beguin Y, Martin S, Deconinck E, Ganser A, Zver S, Lioure B, Rohini R, Koster L, Hayden P, Iacobelli S, Robin M, Yakoub-Agha I. Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP. Bone Marrow Transplant 2022; 57:896-902. [PMID: 35352038 DOI: 10.1038/s41409-021-01555-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Revised: 08/25/2021] [Accepted: 12/15/2021] [Indexed: 11/09/2022]
Abstract
Recently a new three-group clinical classification was reported by an International Consortium to stratify CMML patients with regard to prognosis. The groups were defined as follows: (1) Myelodysplastic (MD)-CMML: WBC ≤ 10 × 109/l, circulating immature myeloid cells (IMC) = 0, no splenomegaly; (2) MD/MP (overlap)-CMML: WBC 10-20 × 109/l or WBC ≤ 10 × 109/l but IMC > 0 and/or splenomegaly; (3) Myeloproliferative (MP)-CMML: WBC > 20 × 109/l. By analysing EBMT Registry patients who underwent allo-HCT for CMML between 1997 and 2016, we aimed to determine the impact of this classification on transplantation outcome and to make a comparison with the conventional WHO classification (CMML-0/CMML-1/CMML-2). Patient grouping was based on the data registered at time of transplantation, with IMC replaced by peripheral blasts. Among 151 patients included in the analysis, 38% were classified as MD-CMML, 42% as MD/MP-CMML and 20% as MP-CMML. With a median survival of 17 months in the whole series, MD-CMML patients were distinguished as a low-risk group with higher CR rate at transplant and a longer post-transplant 2-year progression-free survival in comparison to others (44.5% vs 33.5%, respectively), whereas the WHO classification was superior in identifying high-risk patients (CMML-2) with inferior survival outcomes.
Collapse
Affiliation(s)
- Francesco Onida
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico-University of Milan, Milan, Italy.
| | | | | | - Katja Sockel
- University Hospital Dresden, TU Dresden, Dresden, Germany
| | | | - Jorge Sierra
- Hospital Santa Creu i Sant Pau, Barcelona, Spain
| | | | | | - Xavier Poiré
- Cliniques Universitaires St. Luc, Brussels, Belgium
| | - Luděk Raida
- Department of Hemato-Oncology-Faculty Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
| | - Jean Henri Bourhis
- Gustave Roussy, Institut de Cancérologie, Val-de-Marne, Villejuif, France
| | | | | | | | | | - Yves Beguin
- CHU of Liege and University of Liege, Liege, Belgium
| | | | | | | | - Samo Zver
- University Medical Center, Ljubljana, Slovenia
| | | | | | - Linda Koster
- EBMT Data Office Leiden, Leiden, The Netherlands
| | - Patrick Hayden
- Department of Haematology, Trinity College Dublin, St. James's Hospital, Dublin 8, Ireland
| | | | | | | |
Collapse
|
2
|
Turcsányi P, Kriegova E, Henzlova L, Raida L, Urbanova R, Papajik T. Venetoclax-failed monotherapy in B-lymphoproliferative neoplasms responded to combination of venetoclax with immunochemotherapy: A report of two cases. Leuk Res 2020; 94:106373. [PMID: 32466828 DOI: 10.1016/j.leukres.2020.106373] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2020] [Revised: 05/02/2020] [Accepted: 05/06/2020] [Indexed: 11/25/2022]
Affiliation(s)
- P Turcsányi
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
| | - E Kriegova
- Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - L Henzlova
- Department of Nuclear Medicine, University Hospital, Olomouc, Czech Republic
| | - L Raida
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - R Urbanova
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| | - T Papajik
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
| |
Collapse
|
3
|
Jindra P, Raida L, Karas M, Szotkowski T, Lysák D, Hrabětová M, Jungová A, Steinerová K, Faber E, Papajík T. Allogeneic Stem Cell Transplantation in Patients With FLT3-ITD Mutated AML: Transplantation in CR1 Is the Decisive Factor for Good Outcome. Clin Lymphoma Myeloma Leuk 2019; 19:462-469. [PMID: 31109905 DOI: 10.1016/j.clml.2019.04.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/02/2019] [Revised: 04/07/2019] [Accepted: 04/15/2019] [Indexed: 10/27/2022]
Abstract
BACKGROUND Patients with internal tandem duplication in fms-related tyrosine kinase receptor gene 3 (FLT3-ITD)-mutated acute myeloid leukemia (AML) have a dismal prognosis and the only curative option seems to be allogeneic stem cell transplantation (alloSCT). However, its timing is still matter of debate. PATIENTS AND METHODS We retrospectively analyzed 73 consecutive AML patients with FLT3-ITD (median age 53, range 20-68 years) allografted with consistent policy to try to refer them all for upfront alloSCT in first complete remission (CR1). RESULTS With a median follow-up of 44 (range, 5-135) months the 5-year overall survival (OS)/disease-free survival (DFS) probabilities were 49%/47%. The cumulative incidence of relapse and nonrelapse mortality (NRM) were 37% and 14%, respectively. The estimated 5-year OS for patients who received transplantation in CR1 was 62% versus 0% for patients who received transplantation beyond CR1. Multivariable analysis identified stem cell transplantation beyond CR1 as the key factor for poor OS (hazard ratio [HR], 5.41; P < .0001), DFS (HR, 4.41; P = .0002), and high relapse incidence (HR, 8.08; P < .0001). Acute graft versus host disease Grade ≥3 predicted higher NRM (HR, 3.80; P = .059) as well as inferior OS (HR, 2.04; P = .0079). No association of patient age, nucleophosmin status, donor type, conditioning, and other variables on the survival was detected. CONCLUSION AlloSCT should be regarded with urgency as soon as CR1 is achieved in this subset of AML patients.
Collapse
Affiliation(s)
- Pavel Jindra
- Department of Haematology and Oncology, University Hospital, Pilsen, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
| | - Luděk Raida
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - Michal Karas
- Department of Haematology and Oncology, University Hospital, Pilsen, Czech Republic
| | - Tomáš Szotkowski
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - Daniel Lysák
- Department of Haematology and Oncology, University Hospital, Pilsen, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic
| | - Marcela Hrabětová
- Department of Haematology and Oncology, University Hospital, Pilsen, Czech Republic
| | - Alexandra Jungová
- Department of Haematology and Oncology, University Hospital, Pilsen, Czech Republic
| | - Kateřina Steinerová
- Department of Haematology and Oncology, University Hospital, Pilsen, Czech Republic
| | - Edgar Faber
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - Tomáš Papajík
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| |
Collapse
|
4
|
Valkova V, Jircikova J, Trnkova M, Steinerova K, Keslova P, Lanska M, Koristek Z, Raida L, Krejci M, Kruntoradova K, Dolezal T, Benesova K, Cetkovsky P, Trneny M. The quality of life following allogeneic hematopoietic stem cell transplantation - a multicenter retrospective study. Neoplasma 2019; 63:743-51. [PMID: 27468878 DOI: 10.4149/neo_2016_511] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
UNLABELLED Although allogeneic haematopoietic stem cell transplantation (allo-HSCT) offers a unique curative potential, it may be connected with high treatment-related morbidity and mortality. Besides many organ complications, allo-HSCT may significantly affect quality of life (QOL). PATIENTS AND METHODS Between January 2011 and December 2012, five hundred and ninety patients (pts) from 6 transplant centers in the Czech Republic filled in the questionnaire for the quantitative measurement of QOL using Functional Assessment of Cancer Therapy-General (FACT-G) version 4. Study cohort characteristics were as follows: 325 males, 340 pts received myeloablative conditioning, 383 pts received PBPC, representation of diagnoses; acute leukemia (n=270), bone marrow failure (n=36), chronic myeloid leukemia (n=74), myelodysplastic/myeloproliferative syndrom (n=110), lymphoproliferative disease (n=93). The median age at allo-HSCT was 43 years (range: 1.7 - 71.0), the median time from allo-HSCT to questionnaire completing was 3.8 years (range: - 0.2 - 21.6). The earliest allo-HSCT was performed in November 1989, the last in September 2012. In this retrospective study, we investigated the impact of various factors on the QOL after allo-HSCT: age, gender, diagnosis, type of conditioning, time from diagnosis to allo-HSCT, disease stage, graft type, donor type, time from allo-HSCT to questionnaire completing, GVHD, relapse. Only data from patients who were more than 3 months after allo-HSCT were used for the multivariate analysis. The overall results of the total FACT-G score (median=85.0; range: 29-108) as well as the results of each specific dimension - PWB (median=23.0; range: 5-28), SWB (median=24.0; range: 7-28), EWB (median= 19.0; range: 4-24), FWB (mean=21.0; range: 2-28) showed a value in the highest quartile of the possible evaluation. In multivariate analysis, an inferior QOL score was reported for patients with aGVHD (p=0.002), cGVHD (p<0.001), QOL decreased with increasing age (p=0.048) and increased with time elapsed since allo-HSCT (p<0.001).Allogeneic HSCT represents an important intervention into the overall integrity of the organism. In particular, the development of GVHD can cause very serious organ, but also mental problems which can significantly reduce the QOL. The QOL is steadily increasing with increasing interval from allo-HSCT but improvement and disappearance of these complications may take many years, and sometimes these effects may probably persist permanently.
Collapse
|
5
|
Vráblová L, Blahutová Š, Čermáková Z, Raida L, Szotkowski T, Hubáček J, Rohoň P, Urbanová R, Indrák K, Papajík T, Kolář M, Faber E. Granulocyte transfusions collected after steroid priming for severe infections during neutropenia: A single center experience. Transfus Clin Biol 2018; 26:299-303. [PMID: 30361134 DOI: 10.1016/j.tracli.2018.09.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2018] [Accepted: 09/26/2018] [Indexed: 10/28/2022]
Abstract
BACKGROUND There is no universally accepted opinion on the use of granulocyte transfusions collected using apheresis (GTA) in neutropenic patients and severe infection. PATIENTS AND METHODS The efficacy and safety of GTAs transfused at a single center over 10 years were analyzed retrospectively. GTAs were harvested from voluntary unrelated donors after priming with methylprednisolone using continuous apheresis and hydroxyethylstarch as sedimentation agent. RESULTS 41 patients with neutropenia and hematologic malignancy (15 females and 26 males aged 22-69 (median 45.5)) were given a median 3.5 GTAs per patient (range: 1-17) containing a median 1.39×1010 granulocyte/GTA (range: 0.65-2.81). The indications for GTA use were soft tissue inflammation, sepsis, and pneumonia in 30, 22, and 14 cases, respectively. After GTA complete (30 patients: 73.2%) or partial (6 patients: 14.6%) healing of the infection was achieved. The success rate was 91.7% in soft tissue infections, 66.7% in invasive fungal infections, and 68% in sepsis. Septic shock (documented in 12 cases) was associated with a poor response (P<0.03; Chi-square test). Clinical worsening was observed in six cases (14.6%); four patients died. No significant short-term side effects of GTA treatment were recorded. CONCLUSIONS In our study GTAs collected after steroid priming and used for the treatment of infection during severe neutropenia have shown comparable efficacy with several previously reported trials. However retrospective fashion of our study and inhomogeneous group of patients do not allow any firm conclusions. Prospective studies (including patients' registries) are needed for the better clarification of the role and the dose of GTAs necessary for the successful infection management during neutropenia.
Collapse
Affiliation(s)
- Lucia Vráblová
- Department of Hemato-oncology, Faculty Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, I.P. Pavlova 6, 77520 Olomouc, Czech Republic
| | - Šárka Blahutová
- Institute of Laboratory Hematology and Transfusiology, Department of Biomedical Sciences, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
| | - Zuzana Čermáková
- Institute of Laboratory Hematology and Transfusiology, Department of Biomedical Sciences, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
| | - Luděk Raida
- Department of Hemato-oncology, Faculty Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, I.P. Pavlova 6, 77520 Olomouc, Czech Republic
| | - Tomáš Szotkowski
- Department of Hemato-oncology, Faculty Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, I.P. Pavlova 6, 77520 Olomouc, Czech Republic
| | - Jaromír Hubáček
- Department of Hemato-oncology, Faculty Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, I.P. Pavlova 6, 77520 Olomouc, Czech Republic
| | - Peter Rohoň
- Department of Hemato-oncology, Faculty Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, I.P. Pavlova 6, 77520 Olomouc, Czech Republic
| | - Renata Urbanová
- Department of Hemato-oncology, Faculty Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, I.P. Pavlova 6, 77520 Olomouc, Czech Republic
| | - Karel Indrák
- Department of Hemato-oncology, Faculty Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, I.P. Pavlova 6, 77520 Olomouc, Czech Republic
| | - Tomáš Papajík
- Department of Hemato-oncology, Faculty Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, I.P. Pavlova 6, 77520 Olomouc, Czech Republic
| | - Milan Kolář
- Department of Microbiology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
| | - Edgar Faber
- Department of Hemato-oncology, Faculty Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, I.P. Pavlova 6, 77520 Olomouc, Czech Republic.
| |
Collapse
|
6
|
Holý O, Matoušková I, Zatloukalová S, Dvořáčková M, Petrželová J, Raida L, Růžička F. [Prevalence of strains of Staphylococcus epidermidis and other coagulase-negative staphylococci with biofilm-forming ability at a department of hemato-oncology]. Klin Mikrobiol Infekc Lek 2018; 24:68-72. [PMID: 30747987] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
OBJECTIVES Staphylococcus epidermidis and coagulase-negative staphylococci generally are important causative agents of hospital-acquired infections. A significant role in this process is played by their common ability to form biofilm, a highly organized community of microorganisms adhering to inert surfaces. The study aimed to determine the prevalence of these bacterial strains and their ability to form biofilm at the Department of Hemato-Oncology, University Hospital Olomouc. MATERIAL AND METHODS Over a period of 12 months, samples of air and swabs from surfaces and staff members were collected. The samples were subjected to standard microbiology tests; coagulase-negative staphylococci were identified. Staphylococcus epidermidis strains were confirmed by polymerase chain reaction and subsequently tested for biofilm formation. RESULTS AND CONCLUSIONS Coagulase-negative staphylococci were found in 81 samples, most commonly swabs from staff members. S. epidermidis accounted for 60 % of all positive results; it was most frequently isolated from surface swabs. Almost half of S. epidermidis strains were able to form biofilm. These strains were found in the environment characterized by cleanliness classes FED-STD-209E (USA) - 10 000 and FED-STD-209E (USA) - 100 000. Thus, they pose a risk for immunocompromised patients staying there. Since coagulase-negative staphylococci were also found in healthcare staff of the department, the staff members may play a key role in the transmission of these microorganisms to patients.
Collapse
Affiliation(s)
- Ondřej Holý
- Department of Public Health, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic, e-mail:
| | | | | | | | | | | | | |
Collapse
|
7
|
Raida L, Kuba A, Rusinakova Z, Szotkowska R, Skoumalova I, Faber E, Szotkowski T, Rohon P, Hubacek J, Indrak K, Pikalova Z, Jarosova M, Divoka M, Langova K, Papajik T. Allogeneic stem cell transplantation after fludarabine, melphalan and thymoglobulin followed by early withdrawal of prophylactic immunosuppression in patients with acute lymphoblastic leukemia - update of single center study. Neoplasma 2017; 64:762-769. [PMID: 28592129 DOI: 10.4149/neo_2017_515] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Presented are updated results of allogeneic hematopoietic stem cell transplantations (HSCTs) in 25 adult patients with acute lymphoblastic leukemia (ALL) in complete remission (CR) after a reduced intensity conditioning (RIC) combining fludarabine (150 mg/m2) and melphalan (140 mg/m2) with thymoglobulin (4.5 mg/kg or recently 4.0 mg/kg) followed by early initiation of reduction and withdrawal of prophylactic posttransplant immunosuppression. The median post-transplant follow-up was 32 (range, 4-87) months. Stable engraftment of donor's hematopoiesis was achieved in all patients. Acute graft versus host disease (GVHD) as well as the chronic one were equally observed in four cases (16%). Five patients (20%) relapsed with ALL in the median of 9 (range, 3-15) months after HSCT. During the above post-transplant follow-up, 4 recipients (16%) died. Disease progression and posttransplant complications were the cause of death in three (12%) and one (4%) of them, respectively. The probabilities of 2-year event-free (EFS) and overall survival (OS) were 70.3% (95% CI 51.9-88.7%) and 86.1% (95% CI 71.6-100%), respectively. Presented study confirmed our previously reported promising results and this approach may be considered as an alternative to traditional HSCTs performed in high-risk patients with ALL.
Collapse
|
8
|
Jindra P, Raida L, Lysak D, Karas M, Papajik T, Jungova A, Mohammadová L, Houdova L. Prognostic factors to predict outcome of reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukemia. Neoplasma 2016; 63:595-600. [PMID: 27268923 DOI: 10.4149/neo_2016_413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Despite advances in immunochemotherapy CLL remains an incurable disease.. Allogeneic haematopoietic cell transplantation (HCT) has proven curative potential with ability to overcome adverse prognostic factors, however due to its toxicity it is generally perceived as the last option. We performed retrospective study to explore the outcomes and possible determinants of survival in the unselected consecutive cohort of 68 CLL patients (median age 59 years) receiving reduced intensity HCT as a part of salvage therapy in 2 Czech centers. The median interval from diagnosis to HCT was 69 months with median 3 of prior regimens, all patients were refractory to purine analogues. 49% of patients were transplanted with advanced (i.e. refractory or progressive disease or CR/PR>3), 38% had high risk cytogenetics. With median follow-up of 35 months the 3-year Kaplan-Meier survival probability for OS and PFS were 39% and 26%, respectively. Altogether 18 patients (26%) have relapsed or progressed. During the follow-up 41 patients died, 32 (78%) of transplant related factors (NRM), the others of relapse or disease progression.Univariate analysis failed to identify any clinical and pre- or post-transplant variables having clear prognostic significance for OS or PFS. The marginal OS advantage favoring HCT performed recently was detected (3-year OS: 31% for HCT until 2006 and 47% thereafter, p=0.0923). In multivariable hazards model only the female donors were associated with shorter OS (HR 2.278, p=0.016) whereas transplanted T-cell> 2.75x108/kg predicted inferior PFS(HR 1.957, p=0.035). No prognostic impact of donor type, age of donor and recipient, HLA mismatch, disease status pre-HCT, number of previous therapy lines, interval from dg. to HCT and number of transplanted hematopoietic cells was found. Our findings support the conclusion that alloHCT is able to overcome well known negative cytogenetic prognostic factors and that preferring male to female donors could be beneficial.
Collapse
|
9
|
Mrazek F, Onderkova J, Königova N, Siffnerova V, Vrana M, Ambruzova Z, Skoumalova I, Petrek M, Raida L. A novel HLA-B allele, HLA-B*35:279, identified by sequencing-based typing in a Czech patient. Int J Immunogenet 2016; 43:246-8. [PMID: 27273911 DOI: 10.1111/iji.12276] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2016] [Revised: 04/07/2016] [Accepted: 05/08/2016] [Indexed: 11/29/2022]
Abstract
The identification of a novel HLA-B*35:279 allele in a Czech patient is described. This allele is identical to the B*35:03:01 variant except the G/A nucleotide exchange at position 652 of the HLA-B gene that corresponds to the amino acid substitution from valine to isoleucine in alpha 3 domain of the HLA-B antigen.
Collapse
Affiliation(s)
- F Mrazek
- Department of Immunology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - J Onderkova
- Department of Immunology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - N Königova
- Department of Immunology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - V Siffnerova
- Department of HLA, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
| | - M Vrana
- Department of HLA, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
| | - Z Ambruzova
- Department of Immunology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - I Skoumalova
- Department of Hemato-Oncology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - M Petrek
- Department of Immunology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - L Raida
- Department of Hemato-Oncology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| |
Collapse
|
10
|
Holý O, Matoušková I, Kubátová A, Hamal P, Svobodová L, Jurásková E, Raida L. Monitoring of Microscopic Filamentous Fungi in Indoor Air of Transplant Unit. Cent Eur J Public Health 2016; 23:331-4. [PMID: 26841147 DOI: 10.21101/cejph.a4062] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2014] [Accepted: 05/15/2015] [Indexed: 11/15/2022]
Abstract
AIM The aim of the study was to control the microbial contamination of indoor air monitored monthly at the Transplant Unit of the University Hospital Olomouc from August 2010 to July 2011. METHODS The unit is equipped with a three-stage air filtration system with HEPA filters. The MAS-100 air sampler (Merck, GER) was used. Twenty locations were singled out for the purposes of collecting a total of 720 samplings of the indoor air. Swabs of the HVAC diffusers at the sampling locations were always carried out after the sampling of the indoor air. RESULTS In total, 480 samples of the indoor air were taken for Sabouraud chloramphenicol agar. In 11 cases (2.29%) the cultivation verified the presence of microscopic filamentous fungi. Only two cases involved the sanitary facilities of a patient isolation box; the other positive findings were from the facilities. The most frequent established genus was Aspergillus spp. (4x), followed by Trichoderma spp. (2x) and Penicillium spp. (2x), Paecilomyces spp., Eurotium spp., and Chrysonilia spp. (1x each). In 2 cases the cultivation established sterile aerial mycelium, unfortunately no further identification was possible. A total of 726 swabs of HVAC diffusers were collected (2 positive-0.28%). The study results demonstrated the efficacy of the HVAC equipment. CONCLUSIONS With the continuing increase in the number of severely immunocompromised patients, hospitals are faced with the growing problem of invasive aspergillosis and other opportunistic infections. Preventive monitoring of microbial air contaminants is of major importance for the control of invasive aspergillosis.
Collapse
Affiliation(s)
- Ondřej Holý
- Department of Preventive Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic
| | - Ivanka Matoušková
- Department of Preventive Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic
| | - Alena Kubátová
- Department of Botany, Faculty of Science, Charles University, Prague, Czech Republic
| | - Petr Hamal
- Department of Microbiology, Faculty of Medicine, Palacký University Olomouc, Olomouc, Czech Republic
| | - Lucie Svobodová
- Department of Microbiology, Faculty of Medicine, Palacký University Olomouc, Olomouc, Czech Republic
| | - Eva Jurásková
- Department of Dentistry and Oral Sciences, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic
| | - Luděk Raida
- Department of Haemato-Oncology, University Hospital Olomouc, Olomouc, Czech Republic
| |
Collapse
|
11
|
Raida L, Rusinakova Z, Szotkowska R, Kuba A, Faber E, Rohon P, Szotkowski T, Hubacek J, Pikalova Z, Jarosova M, Divoka M, Indrak K, Langova K, Skoumalova I, Papajik T. Allogeneic stem cell transplantation after fludarabine, melphalan and thymoglobulin followed by early withdrawal of prophylactic immunosuppression could be an effective approach to patients with acute lymphoblastic leukemia. Neoplasma 2015; 62:805-11. [PMID: 26278139 DOI: 10.4149/neo_2015_097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Presented are results of allogeneic hematopoietic stem cell transplantations (HSCTs) in 13 patients with high-risk acute lymphoblastic leukemia (ALL) in the first complete remission after a reduced intensity conditioning combining fludarabine (150 mg/m2) and melphalan (140 mg/m2) with thymoglobulin (4.5 mg/kg). The immunosuppressive effect of T-cell depletion reducing the risk of graft-versus-host disease (GVHD) and non-relapse mortality was compensated by early initiation of reduction and withdrawal of prophylactic immunosuppression aimed at maintaining effective immunological antileukemic control. The median post-transplant follow-up was 23 (range, 10-65) months. Stable engraftment of donor's hematopoiesis was achieved in all patients. Acute GVHD was observed in two cases (15.4%); the chronic form was not noted. Two patients (15.4%) relapsed with ALL at 3 and 16 months after transplantation. During the above post-transplant follow-up, all 13 recipients were alive, with a probability of 2-year disease-free survival of 76.9% (95% CI 51-100%). Although the results were obtained with a small pilot study group it may be assumed that, given the prognostic risk of most patients and the nearly 2-year median post-transplant follow-up, the approach may be considered as an alternative to HSCTs after traditional myeloablative or reduced conditioning regimens with standard GVHD prophylaxis.
Collapse
|
12
|
Szotkowski T, Faber E, Hubacek J, Raida L, Rohon P, Kuba A, Pikalova Z, Holzerova M, Divoka M, Jarosova M, Vrbkova J, Papajik T, Indrak K. Acute promyelocytic leukemia successfully treated also in elderly patients with significant comorbidities: a 20-year single-center experienc. Neoplasma 2015; 62:146-51. [PMID: 25563379 DOI: 10.4149/neo_2015_019] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
UNLABELLED Acute promyelocytic leukemia is a unique entity among acute leukemias. Introduction of all-trans retinoic acid and, subsequently, arsenic trioxide in its treatment has markedly improved treatment outcomes for this once frequently fatal disease. Improved outcomes have also been observed in elderly patients, including those in whom standard intensive therapy is contraindicated because of comorbidities.In our center, a total of 60 APL patients were treated in 1993-2013, of whom 9 were aged 60 or more years. Although most of them had significant comorbidities at the time of diagnosis, eight achieved complete remission. At the time of the analysis, six patients were alive and in long-term remission; two patients died of causes other than APL. The median follow-up was 59 months.Included is case report of a patient with a high comorbidity score whose treatment was markedly reduced and individualized.Our experience shows that, in APL patients a curative approach is generally tolerated and should always be attempted regardless of age and comorbidities. KEYWORDS APL - elderly patients - comorbidity.
Collapse
|
13
|
Mrazek F, Onderkova J, Szotkowski T, Königova N, Ambruzova Z, Raida L. Somatic mutation in acute myelogenous leukemia cells imitate novel germline HLA-A allele: a case report. ACTA ACUST UNITED AC 2014; 83:414-7. [DOI: 10.1111/tan.12362] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2013] [Revised: 03/07/2014] [Accepted: 03/25/2014] [Indexed: 12/14/2022]
Affiliation(s)
- F. Mrazek
- HLA laboratory, Department of Immunology, University Hospital and Faculty of Medicine and Dentistry; Palacky University; Olomouc Czech Republic
- Institute of Molecular and Translational Medicine, University Hospital and Faculty of Medicine and Dentistry; Palacky University; Olomouc Czech Republic
| | - J. Onderkova
- HLA laboratory, Department of Immunology, University Hospital and Faculty of Medicine and Dentistry; Palacky University; Olomouc Czech Republic
| | - T. Szotkowski
- Department of Haemato-oncology, University Hospital and Faculty of Medicine and Dentistry; Palacky University; Olomouc Czech Republic
| | - N. Königova
- HLA laboratory, Department of Immunology, University Hospital and Faculty of Medicine and Dentistry; Palacky University; Olomouc Czech Republic
| | - Z. Ambruzova
- HLA laboratory, Department of Immunology, University Hospital and Faculty of Medicine and Dentistry; Palacky University; Olomouc Czech Republic
| | - L. Raida
- Department of Haemato-oncology, University Hospital and Faculty of Medicine and Dentistry; Palacky University; Olomouc Czech Republic
| |
Collapse
|
14
|
Procházka V, Papajík T, Faber E, Raida L, Kapitáňová Z, Langová K, Prouzová Z, Jarošová M, Indrák K. Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era. Leuk Lymphoma 2014; 55:1584-90. [DOI: 10.3109/10428194.2013.850167] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
15
|
Jindra P, Muzik J, Indrak K, Zak P, Sabty FA, Kozak T, Cetkovsky P, Karas VKM, Raida L, Szotkowski T. The outcome of allogeneic HSCT in older AML patients is determined by disease biology and not by the donor type: an analysis of 96 allografted AML patients ≥ 50 years from the Czech acute leukaemia clinical register (alert). Neoplasma 2013; 60:576-83. [PMID: 23790178 DOI: 10.4149/neo_2013_075] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Older patients with AML have poor prognosis after chemotherapy and allo-SCT was historically limited to the young patients. In the multicentre retrospective study we analyzed 96 consecutive AML patients ≥ 50 years allografted with related (n=59) or unrelated (n=37) donor. The 2- year OS and DFS rates were 45 % and 42 % for the whole group. The corresponding figures for related patients were 48% and 42% whereas for unrelated 42% and 42%, respectively (OS p=0,721, DFS p= 0,896). The cumulative incidences of relapse (28% of all patients) and NRM mortality (26%) were low with no significant differences among related and unrelated cohorts. Multivariate analysis revealed the only major independent variables associated with an inferior OS were unfavourable cytogenetics (RR 3.36; CI 1.66-6.83; p=0.001) and advanced disease status (RR 2.30; CI 1.21-4.37; p=0.011). Unfavourable cytogenetics (RR 3.00; CI 1.50-5.99; p=0.002) and advanced disease at SCT (RR 2.27; CI 1.22-4.22; p=0.009) were also the only independent variables associated with inferior DFS. In conclusion, our analysis indicates that outcomes of allografted AML patients aged ≥ 50 years are determined by cytogenetic risk category and disease status at transplantation and not by the type of donor.
Collapse
Affiliation(s)
- P Jindra
- University Hospital, Pilsen, Czech Republic.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Holý O, Matoušková I, Raida L. [The incidence of gram-negative bacteria in the environment of the Transplant Unit, Department of Hemato-oncology, University Hospital --Olomouc]. Epidemiol Mikrobiol Imunol 2012; 61:103-109. [PMID: 23301625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
A study entitled "Surveillance of Infectious Complications in Hemato-oncological Patients", was conducted at the Department of Hemato-Oncology, University Hospital Olomouc from 1 July 2010 to 31 August 2011. During the study period, a total of 96 patients were hospitalized at that department and 63 stem cell transplants were performed, 43 autologous and 23 allogeneic. Microbial contamination was monitored in indoor air, on selected surfaces, and in health care providers (right hand smear, left and right nostril swabs and scalp hair smear). Opportunistic Gram-negative bacterial strains were selected from the cultures.
Collapse
Affiliation(s)
- Ondřej Holý
- Ústav preventivního lékařstvi, Lékařska fakulta University Palackého v Olomouci.
| | | | | |
Collapse
|
17
|
Matoušková I, Raida L, Holý O. [The incidence of nonfermentative gram-negative bacilli in the environment of the transplant unit, department of hemato-oncology, university hospital Olomouc]. Epidemiol Mikrobiol Imunol 2012; 61:110-115. [PMID: 23301626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
A study entitled "Surveillance of Infectious Complications in Hemato-oncological Patients" was conducted at the Department of Hemato-Oncology, University Hospital Olomouc from 1 July 2010 to 31 August 2011. During the study period, a total of 63 patients were hospitalized at that department and 33 stem cell transplants were performed, 21 autologous and 12 allogeneic. Microbial contamination was monitored in indoor air, on selected surfaces, and in health care providers (right hand smear, left and right nostril swabs and scalp hair smear). Gram-negative bacteria detected by culture were identified biochemically. Special attention was paid to nonfermentative Gram-negative bacilli which, based on the recent literature, should be considered as emerging causative agents of hospital infections.
Collapse
Affiliation(s)
- Ivanka Matoušková
- Ústav preventivního lékařstvi, Lékařska fakulta University Palackého v Olomouci.
| | | | | |
Collapse
|
18
|
Procházka V, Faber E, Raida L, Langová K, Indrák K, Papajík T. High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma. Leuk Lymphoma 2012; 53:1306-10. [PMID: 22263569 DOI: 10.3109/10428194.2011.654339] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Serum thymidine kinase 1 (TK1) is a sensitive marker of tumor cell proliferation. TK1 has been reported as a reliable prognostic factor in solid tumors and chronic lymphocytic leukemia, but has not yet been tested in large populations of patients with non-Hodgkin lymphoma. In this study, the prognostic significance of TK1 levels was assessed in 170 prospectively enrolled patients with previously untreated follicular lymphoma (FL). The TK1 level at the time of treatment initiation was shown to correlate with the clinical stage, Follicular Lymphoma International Prognostic Index (FLIPI) score, β(2)-microglobulin level, lactate dehydrogenase level and B symptoms. No correlation was found with FL grade or Ki-67 proliferation index. Cox regression analysis identified high TK1 levels (≥ 15I U/L) as a prognostic factor for overall survival (hazard ratio 2.91, p = 0.019) and progression-free survival (hazard ratio 1.94, p = 0.022) independent of FLIPI score variables. Thus, TK1 levels may help to refine risk assessment in the modern immunotherapy era.
Collapse
Affiliation(s)
- Vít Procházka
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | | | | | | | | | | |
Collapse
|
19
|
Prochazka V, Papajik T, Gazdova J, Divoka M, Rozmanova S, Faber E, Raida L, Kucerova L, Langova K, Jarosova M, Indrak K. FcγRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy. Neoplasma 2011; 58:263-70. [PMID: 21395368 DOI: 10.4149/neo_2011_03_263] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Antibody (rituximab) dependent cellular cytotoxicity is a key mechanism in killing CD20+ lymphoma cells. FcγRIIIA-158 V/F gene polymorphism results in expression of 3 variants of the FcγRIIIA receptor (FcγRIIIA) on cytotoxic lymphocytes with different receptor affinity. We studied 102 patients with newly diagnosed FL to assess whether the FcγRIIIA genotype influences outcome in patients treated with risk-adapted immunochemotherapy. The median age was 52 years (31-84); 90% of the patients had advanced (III/IV) clinical stages. The Follicular Lymphoma International Prognostic Index (FLIPI) scores were as follows: low 18.9%, intermediate 33.7% and high 47.4%. The front-line treatment was stratified according to the commonly used risk factors (FLIPI, beta-2-microglobuline and serum-Tyrosine-Kinase levels, bulky disease) into 3 treatment groups: (1) patients with FLIPI 0-1 treated with (R)-CHOP (51%), (2) patients under 60 (65) years of age with intermediate-risk disease (FLIPI 2) indicated for an intensive protocol (ProMACE-CytaBOM or sequential chemotherapy) (21%), and (3) patients under 60 (65) years with high-risk disease (FLIPI ≥3) treated with intensive chemotherapy plus autologous stem cell transplantation (28%). Rituximab was added to front-line chemotherapy in 59% of the patients. Generally, complete remission (CR) or unconfirmed CR was achieved in 85% of the patients, 11% had partial remission and 4% stable disease. Molecular CR (CRm) was achieved in 67.4% of 86 evaluable patients. Overall survival (OS) at 5 years reached 84% (95% CI 0.74-0.93); event-free survival (EFS) at 5 years was 58% (95% CI 0.45-0.71). The frequencies of FcγRIIIA-158 gene polymorphisms V/V, V/F and F/F were 8%, 50% and 42%, respectively. The FLIPI score distribution was not different in F/F patients as compared to V/F+V/V carriers (chi-square, P=0.7). The treatment modalities (treatment arm or rituximab administration) had the same distribution in V/V+V/F vs F/F patients (chi-square, P=0.16 and P=0.62, respectively). The CRm rates were similar in both subgroups of V/V+V/F vs F/F patients (chi-square, P=0.92). Survival curves for OS and EFS were not significantly different when comparing the subgroups of V/V+V/F vs F/F patients (P=0.28 and P=0.57, respectively). We found no difference in the quality of treatment response or survival after front-line immunochemotherapy between FcγRIIIA subgroups. FcγRIIIA polymorphism have no influence on the outcome of patients treated with risk-adapted chemotherapy with or without rituximab.
Collapse
Affiliation(s)
- V Prochazka
- Department of Hemato-Oncology, University Hospital, I.P. Pavlova 6,77520 Olomouc, Czech Republic.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Raida L, Tucek P, Vondrakova J, Rusinakova Z, Faber E, Indrak K. Comparison of Conditioning Regimens BU-CY and FLU-BU12-TG Used in the Patients Undergoing Allogeneic Stem Cell Transplantation (SCT) for Acute Myeloid Leukemia (AML). Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
21
|
Mociková H, Pytlík R, Raida L, Sýkorová A, Marková J, Král Z, Jindra P, Steinerová K, Válková V, Trnková M, Vacková B, Trnený M, Indrák K, Belada D, Mayer J, Koza V, Kozák T. [Treatment of patients with relapsed/refractory Hodgkin lymphoma]. Klin Onkol 2011; 24:121-125. [PMID: 21644367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
BACKGROUNDS This retrospective study evaluated treatment outcomes in patients undergoing autologous stem cell transplantation (ASCT) for relapsed/refractory Hodgkin lymphoma (HL). PATIENTS AND METHODS Overall, 194 HL patients treated with ASCT between 2000 and 2009 were analyzed. Survival was calculated using Kaplan-Meier method and differences in survival between subgroups with log-rank test. RESULTS Best responses observed after ASCT: 124 complete and 35 partial remissions, 2 patients with stable disease and 33 relapses/progressions. During a median follow-up of 44 months, seventy patients after ASCT progressed/relapsed. Thirty-seven patients received salvage chemotherapy only with or without radiotherapy, 25 underwent allogeneic stem cell transplantation (SCT), 4 the second ASCT and 4 refused treatment. 5-year overall survival after ASCT was 71% and progression-free survival 54%. Median survival of the 70 patients relapsing after ASCT was 16.9 months. Median survival in patients after allogeneic SCT was 31.8 months and 12.4 months in patients treated with other modalities (p = 0.21). Overall mortality was 26.3% (51/194 patients): 13.4% progressions/relapses of HL and 12.9% non-relapse mortality. CONCLUSION Efficacy of ASCT was confirmed in 54% progression-free survivors. Median survival after ASCT failure is relatively short. There is a slightly longer overall survival after allogeneic SCT, although not statistically significant when compared to other approaches.
Collapse
Affiliation(s)
- H Mociková
- Oddelení klinické hematologie, FN Královské Vinohrady Praha.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Papajík T, Mysliveček M, Sedová Z, Buriánková E, Procházka V, Koranda P, Raida L, Kubová Z, Palová M, Kučerová L, Flodr P, Jarkovský J, Dušek L, Indrák K. Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma. Eur J Haematol 2010; 86:32-7. [PMID: 20874822 DOI: 10.1111/j.1600-0609.2010.01532.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
OBJECTIVES Positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose ((18) F-FDG) is considered to be the most beneficial imaging method for staging patients with non-Hodgkin's lymphoma (NHL). The intensity of (18) F-FDG accumulation may be determined by calculating the so-called standardised uptake value (SUV). The study aimed at assessing the benefit of SUV(max) determination in staging (18) F-FDG PET/CT in untreated patients with NHL. METHODS One hundred and forty-nine initial staging (18) F-FDG PET/CT scans performed in patients with NHL between January 2007 and August 2009 were assessed, and the SUV(max) was determined. RESULTS The highest mean and median values of SUV(max) were observed in patients with diffuse large B-cell lymphoma (DLBCL), the lowest mean and median values were found in small lymphocytic lymphoma. The overlap in SUV(max) < 10 between DLBCL and the other subgroups of NHL was very significant. Statistically, no correlation was found between the lactate dehydrogenase and SUV(max) values. On the other hand, a correlation of the Ki-67 proliferative index of tumour cells and SUV(max) was revealed (r = 0.409, P < 0.001). The geometric mean of SUV(max) in patients with Ki-67 ≤ 60 and those with Ki-67 > 60 was 8.8 and 14.3, respectively (P < 0.001). CONCLUSIONS The results confirm that SUV(max) is not beneficial for making a more precise diagnosis in most patients with NHL. Correlation of SUV(max) with the Ki-67 values suggests that SUV(max) might have a prognostic values in NHL.
Collapse
Affiliation(s)
- Tomáš Papajík
- Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Jarosová M, Papajík T, Holzerová M, Dusek L, Pikalová Z, Lakomá I, Raida L, Faber E, Divoká M, Vlachová S, Prekopová I, Novosadová A, Pospísilová H, Indrák K. High Incidence of Unbalanced Chromosomal Changes in Mantle Cell Lymphoma Detected by Comparative Genomic Hybridization. Leuk Lymphoma 2009; 45:1835-46. [PMID: 15223644 DOI: 10.1080/10428190410001683796] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Comparative genomic hybridization (CGH) was carried out in 30 mantle cell lymphoma (MCL) patients at the time of diagnosis. CGH results were supported by conventional cytogenetics (CC), FISH, molecular genetic PCR methods and 2 patients were examined by array CGH. Using all cytogenetic, molecular cytogenetic and PCR methods, chromosomal changes were detected in 28 (93%) patients. Using CGH, unbalanced chromosomal changes were detected in 24 (80%) cases. The most frequent aberrations were losses of 1p (8 cases), 8p (10 cases), 9q (6 cases), 11q (11 cases), 13q (10 cases) and 17p (9 cases), and gains of chromosome 3 and 3q (12 cases) and 8q (7 cases). Total number of 60 gains and 116 losses were detected. The primary chromosomal change t(11;14) was detected using FISH and/or PCR in 20 (66.6%) patients, and in 9 of them, the breakpoint was determined using PCR in the major translocation cluster (MTC). The evaluation of the frequencies of CGH changes in groups of patients with and without t(11;14) revealed the differences only in losses 6q and 9q, which were only found in patient with t(11;14). An important result was obtained using array CGH method. In a patient without the primary t(11;14), the gain of CCND1 gene was found. Our results show high heterogeneity of the additional chromosomal changes in MCL cases, which involved specific chromosomal subregions. We did not confirm the importance of subdividing of MCL cases with and without t(11;14). Also, statistical significance in survival rates between both subgroups was not confirmed.
Collapse
Affiliation(s)
- M Jarosová
- Department of Hemato-Oncology, University Hospital, Olomouc, Czech Republic.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Rusináková Z, Raida L, Faber E, Tomková J, Bednaríková J, Indrák K, Novotný D. [Toxoplasmosis after immunosuppressive therapy--our experience]. Klin Mikrobiol Infekc Lek 2009; 15:95-98. [PMID: 19637140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Toxoplasmosis is a parasitic disease associated with high mortality in immunocompromised patients. It may lead to life-threatening conditions, usually neuroinfections, pneumonia or disseminated disease. It may be potentially dangerous, especially for patients with prolonged lymphopenia or those treated with immunosuppressive drugs. In our centre, we have observed 3 cases of toxoplasmosis in patients after allogeneic haematopoietic stem cell transplantation (HSCT) (2.6% of 116 allo-HSCT patients since 2000) and one case after autologous HSCT (0.3% of 395 auto-HSCT patients since 1997). Toxoplasmosis is manifested by neurological symptoms including hemiparesis and paraparesis, cerebral salt-wasting syndrome (hyponatraemia and hypoosmolality), psychoorganic syndrome and signs of respiratory infection. The diagnosis was made by combining clinical signs and results of PCR and CT examinations. The patients were treated with high-dose pyrimethamine, clindamycin, co-trimoxazole and folic acid. Three of the four patients have survived with no signs of the disease. One patient died prior to treatment. The increasing use of highly immunosuppressive chemotherapy and conditioning regimens (including rituximab, fludarabine and anti-thymocyte globulin) is associated with a significant risk of toxoplasmosis. Variable manifestations, non-specific results of MRI or CT examinations and possibility of PCR negativity are the main obstacles to successful diagnosis.
Collapse
Affiliation(s)
- Z Rusináková
- Hemato-onkologická klinika Fakultní nemocnice, University Palackého Olomouc, Czech Republic.
| | | | | | | | | | | | | |
Collapse
|
25
|
Ambruzova Z, Mrazek F, Raida L, Faber E, Onderkova J, Kriegova E, Indrak K, Petrek M. Association of IL-6 gene polymorphism with the outcome of allogeneic haematopoietic stem cell transplantation in Czech patients. Int J Immunogenet 2009; 35:401-3. [PMID: 18976446 DOI: 10.1111/j.1744-313x.2008.00798.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Interleukin-6 (IL-6) is an important pro-inflammatory mediator implicated in immune-mediated complications of allogeneic haematopoietic stem cell transplantation (aHSCT). In accord with previous reports, this preliminary study on 56 donor-recipient pairs revealed IL-6-174 single nucleotide polymorphisms as a risk factor for the development of acute graft-versus-host disease and decreased survival after aHSCT.
Collapse
Affiliation(s)
- Z Ambruzova
- Department of Immunology, Tissue Typing Laboratory, Palacky University Olomouc, Czech Republic
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Ambruzova Z, Mrazek F, Raida L, Jindra P, Vidan-Jeras B, Faber E, Pretnar J, Indrak K, Petrek M. Association of IL6 and CCL2 gene polymorphisms with the outcome of allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2009; 44:227-35. [PMID: 19234509 DOI: 10.1038/bmt.2009.16] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Various polymorphisms of non-HLA genes have recently been investigated as candidate risk factors in allogeneic haematopoietic SCT (aHSCT). Our study aimed at exploring possible associations of IL6 and CCL2 single nucleotide polymorphisms (SNP) with aHSCT outcome. A total of 166 HLA-identical aHSCT pairs recruited in were genotyped for IL6 -174 G/C, IL6 -597 G/A, CCL2 -2518 A/G and CCL2 -2076 A/T SNPs by PCR with sequence-specific primers (PCR-SSP). The association between IL6 -174 GG genotype and increased risk of acute GVHD was found in whole study group (P=0.03) and in the subgroup of related aHSCT (P=0.01), association between IL6 -597 GG genotype and the occurrence of acute GVHD was detected only in the related aHSCT pairs (P=0.02). Furthermore, reduction in OS was revealed among recipients possessing IL6 -174(*)G allele in the group of related aHSCT pairs (P=0.04). Presence of CCL2 -2076 TT genotype was associated with decrease of OS (P=0.04) and increase of TRM (P=0.02) in patients transplanted by related donor. These results, in the context of previous findings, suggest that IL6 gene polymorphisms may be associated with aHSCT outcome, particularly in patients transplanted from a related donor.
Collapse
Affiliation(s)
- Z Ambruzova
- Department of Immunology, Palacky University and University Hospital, Olomouc, Czech Republic
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Raida L, Vondrakova J, Faber E, Papajik T, Indrak K, Langova K. 187: Fludarabin and Cyclophosphamide Based Non-Myeloablative Conditioning Regimens in the Patients Allografted for Recurrent/Refractory Malignant Lymphoproliferative Disorders. Biol Blood Marrow Transplant 2008. [DOI: 10.1016/j.bbmt.2007.12.196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
28
|
Papajik T, Raida L, Faber E, Vondrakova J, Prochazka V, Kubova Z, Skoumalova I, Jarosova M, M LK, Paucek B, Myslivecek M, Neoral C, Oral I, Jarkovsky J, Dusek L, Indrak K. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission. Neoplasma 2008; 55:215-221. [PMID: 18348654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Improved survival has been observed in poor-risk diffuse large B-cell lymphoma (DLBCL) patients treated with high-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) in first complete remission. Retrospective studies have suggested that HDT with ASCT can improve survival also in partial responders but some doubts about the advantage of intensive therapy in such patients still remain. We evaluated retrospectively the results of HDT and ASCT in 55 patients with confirmed DLBCL treated between May 1999 and July 2006. Thirty-six patients (65%) showed partial remission (PR) and 19 patients (35%) reached complete remission (CR) after induction treatment with (44%) or without (56%) concomitant rituximab (R) immunotherapy. After HDT and ASCT, 69% of patients fulfilled the criteria of CR, 22% had unconfirmed CR (CRu), 7% remained in PR and 1 patient (2%) relapsed. Twenty patients in PR after the induction treatment reached CR after ASCT, 12 other PR patients achieved CRu. The 5-year event-free survival (EFS) of the 55 transplanted patients was 76% (95% confidence interval /CI/, 63% to 89%) and the 5-year overall survival (OS) was 85% (95% CI, 73% to 97%). The EFS and OS rates differed significantly only between patients younger than 40 years and older groups (p=0.022 and p=0.046, respectively). On univariate analysis of prognostic factors, EFS and OS were not affected by any of the following: age, sex, stage, subtype of DLBCL, initial lactate dehydrogenase, beta-2-microglobulin and serum thymidine kinase levels, International Prognostic Index (IPI) and age-adjusted IPI scores, induction treatment with or without rituximab and type of primary therapeutic response (CR vs PR). These results show that first-line HDT and ASCT for adults up to the age of 65 years with poor-risk DLBCL is a feasible and effective treatment option even in the era of R-chemotherapy in CR as well as for patients in PR.
Collapse
Affiliation(s)
- T Papajik
- Department of Hemato-oncology, University Hospital Olomouc, I.P. Pavlova 6, Olomouc, Czech Republic.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Matejková E, Ocadlíková D, Smejkalová J, Muzíkova J, Raida L, Tousovská K, Pacasová R, Nenicková M, Tesarová E, Sterba J, Indrák K, Michálek J. [Selective depletion of alloreactive T cells and study of anti-tumor activity of specific T cell clones in patients with leukemia]. Klin Onkol 2008; 21:104-109. [PMID: 19097419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
BACKGROUND Graft-versus-host disease (GVHD) is a severe complication of allogeneic transplantation of hematopoietic stem cells. Donor T cells play a major role in GVHD leading to the host tissue damage, mainly the skin, liver, and gastrointestinal tract. A selective depletion using an anti-CD25 immunotoxin can eliminate harmful alloreactive T cells while preserving other donor T cells with antileukemic and antiinfectious reactivity. PATIENTS AND METHODS We performed 15 mixed lymphocyte reactions with clinical specimens from 12 patients with various types of leukemia (7x AML, 3x ALL, 1x CML, 1x CLL) and PBMC from 15 healthy volunteers from Transfusive station FN Brno Bohunice. RESULTS In our experiments we have demonstrated, that antileukemic (GVL) effect of donor, especially CD4+ T cells was well preserved (7.46%), while unfavourable alloreactive (GVH) reaction of donor T cells was completely removed. The graft-versus-host (GVH) reactivation of donor cells was negligible ever after repeated stimulation with irradiated patient's PBMC. CONCLUSION We have shown that anti-CD25 immunotoxin (IT), RFT5-SMPT-dgA, launched against alpha chain for human interleukin 2 (IL-2), led to long-term selective depletion of alloreactive donor T cell clones while their antileukemic activity was well preserved. Base on our results the clinical phase I/II study was designed. This study was initiated in year 2007 in three clinical centers in Czech Republic.
Collapse
Affiliation(s)
- E Matejková
- Univerzitní Centrum Bunecné Imunoterapie, Masarykova Univerzita, Brno.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Szotkowski T, Hubacek J, Faber E, Raida L, Jarošová M, Pikalova Z, Indrák K. P013 All-transretinoic acid (ATRA) in the treatment of acute promyelocytic leukemia - 15 years of single centre experience. Leuk Res 2007. [DOI: 10.1016/s0145-2126(07)70361-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
31
|
Papajik T, Raida L, Faber E, Prochazka V, Vondrakova J, Skoumalova I, Kubova Z, Jarosova M, Jarkovský J, Dusek L, Indrak K. P201 High-dose therapy and autologous transplantation in poor prognosis patients with diffuse large B-cell lymphoma in first remission. Blood Rev 2007. [DOI: 10.1016/s0268-960x(07)70097-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
32
|
Faber E, Zapletalová J, Skoumalová I, Holzerová M, Veselovská J, Rožmanová Š, Rohoň P, Solná R, Raida L, Marešová I, Klusová N, Divoký V, Jarošová M, Indrák K. O39 Treatment of chronic myeloid leukemia in Northern Moravia: results during the period 1990 2005. Blood Rev 2007. [DOI: 10.1016/s0268-960x(07)70056-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
33
|
Raida L, Faber E, Mrazek F, Indrak K, Petrek M, Ambruzova Z, Kriegova E, Onderkova J, Zapletalova J. 264: Influence of interleukin-6 (IL-6) gene polymorphism on the outcome of patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007. [DOI: 10.1016/j.bbmt.2006.12.269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
34
|
Raida L, Papajík T, Indrák K, Herman M, Paucek B, Zapletalová J. [Chemotherapy of BOVAPEC in the primary treatment of Hodgkin's lymphoma intermediate stages]. Vnitr Lek 2007; 53:31-7. [PMID: 17472013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
DESIGN Chemotherapy of BOVAPEC is the modification of temporary intensified Stanford V protocol, an effective primary treatment of advanced Hodgkin's lymphoma (HL) in spite of limited toxicity. Nitrogen mustard was substituted by less myelotoxic cyclophosphamide and the protocol has been used in the treatment of patients with an intermediate stage of HL. METHODS The primary treatment with BOVAPEC was started in 62 patients. Complete chemotherapy schedule was administered to 60 patients (97%) and the median of its overall duration was 13 (12-18) weeks. 31 patients (50 %) underwent adjuvant "involved field" radiotherapy (RT). The median of posttherapeutic follow-up was 37 (range 8-85) months. RESULTS During the treatment, a neutropenia of grade 3 and 4 was observed in 14 patients (23%) but without the development of any serious infectious complications. The manifestation of early non-hematological toxicity did not overcome grade 2.58 patients (94%) achieved the complete remission of HL. A relapse was observed in 11 cases (19%) and estimated five years disease-free survival (DFS) is 72%. The combination of BOVAPEC and RT in primary treatment was associated with higher probability of five years DFS but actually without statistical significance (88% vs. 58%; p = 0.08). CONCLUSION The BOVAPEC regimen with its acceptable toxicity may represent effective primary therapeutic approach to the patients with the intermediate stage of HL. Adjuvant RT is essential in all patients diagnosed with nodal bulk and/or residual lymphadenomegaly.
Collapse
Affiliation(s)
- L Raida
- Hemato-onkologická klinika Lékarské fakulty UP a FN Olomouc.
| | | | | | | | | | | |
Collapse
|
35
|
Mrazek F, Fae I, Ambruzova Z, Raida L, Kriegova E, Indrak K, Fischer GF, Petrek M. A single amino acid exchange shifts the serological reactivity of the novel HLA-B*4442 allele product from HLA-B44 to HLA-B21. Int J Immunogenet 2006; 33:197-200. [PMID: 16712651 DOI: 10.1111/j.1744-313x.2006.00596.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A novel HLA-B (human leukocyte antigen-B) allele, HLA-B*4442, was identified both in a Czech patient with leukaemia and in his mother. The presence of a novel allele was initially suspected because conflicting results were obtained by serological and DNA typing techniques. The HLA typing using the polymerase chain reaction-sequence-specific primers (PCR-SSP) at the two-digit level indicated an allele belonging to the HLA-B*44 group, whereas serological typing indicated HLA-B21. Typing with PCR-sequence-specific oligonucleotides (PCR-SSO) resulted in a unique reaction pattern that could not be assigned to a known allele, PCR-SSP typing at the four-digit level did not match any known B*44 allele, either. The sequencing-based typing of the HLA-B locus then revealed the novel B*4442 allele that is identical with B*4405 except a single C-->G nucleotide exchange at position 572. This exchange results in an amino acid substitution from serine to tryptophan at position 167 of the expressed HLA-B protein. The B21 serological reactivity of the novel B*4442 allele product was confirmed by employing an additional serological panel of typing sera. Our findings support previous reports claiming that serine at the position 167 in the alpha-2 domain of the HLA-B protein is a major determinant of the HLA-B44(12) serological epitope.
Collapse
Affiliation(s)
- F Mrazek
- Tissue Typing Laboratory, Department of Immunology, Medical Faculty Palacky University, Olomouc, Czech Republic.
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Faber E, Vondrakova J, Zapletalova J, Skoumalova I, Maresova I, Raida L, Papajik T, Indrak K. Prognostic factors for survival of patients with non-hodgkin’s lymphoma (NHL) after autologous peripheral stem cell transplantation (APSCT)—single center experience. Biol Blood Marrow Transplant 2006. [DOI: 10.1016/j.bbmt.2005.11.368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
37
|
Papajik T, Faber E, Raida L, Prochazka V, Vondrakova J, Rozmanova S, Jarosova M, Indrak K. Myeloablative chemotherapy and autologous stem cell transplantation in poor prognosis patients with advanced follicular lymphoma—effective therapy in first complete or partial remission. Biol Blood Marrow Transplant 2006. [DOI: 10.1016/j.bbmt.2005.11.353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
38
|
Mrazek F, Fae I, Ambruzova Z, Raida L, Indrak K, Petrek M, Fischer GF. A novel HLA-B*420502 allele identified by PCR-SSO/SSP routine typing and confirmed by Sequencing-based typing. ACTA ACUST UNITED AC 2005; 65:275-7. [PMID: 15730521 DOI: 10.1111/j.1399-0039.2005.00376.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A novel human leukocyte antigen-B (HLA-B) allele, B*420502, was identified in a patient with leukemia (Caucasoid, Czech ancestry) and his mother during intrafamily search for the hematopoietic stem cell donor. The novel allele was initially detected by HLA typing at low resolution using both sequence specific primers and sequence specific oligonucleotides techniques that resulted in unique reaction patterns. The alleles of the HLA-B locus were separated by the haplotype-specific extraction technique. Sequencing of those alleles revealed a novel allele, B*420502, that is identical with B*420501 except a T-->G exchange (synonymous mutation) at position 618.
Collapse
Affiliation(s)
- F Mrazek
- Department of Immunology,Tissue Typing Laboratory, Medical Faculty, Palacky University Olomouc, Czech Republic.
| | | | | | | | | | | | | |
Collapse
|
39
|
Raida L, Faber E, Papajik T, Vlachova S, Jarosova M. An efficacy of interferon-α (IFN-α) and interleukin-2 (IL-2) in the treatment of hematological malignancies relapse-persistence-progression after the allogeneic nonmyeloablative stem cell transplantation (NSCT). Biol Blood Marrow Transplant 2004. [DOI: 10.1016/j.bbmt.2003.12.233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
40
|
Raida L, Faber E, Papajík T, Heczko M, Skoumalová L, Pikalová Z, Jaroová M, Koupilová M, Kubaláková R, Divoká M, Indrák K, Hubáèek J. 198The choice of conditioning regimen regarding the host T-cell levels seems to be an effective way how to achieve the donor cells engraftment including effective tumour control and reduce the toxicity of some non-myeloablative allogeneic stem cell transplantations in lymphomas. Biol Blood Marrow Transplant 2003. [DOI: 10.1016/s1083-8791(03)80191-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
41
|
Raida L, Papajík T, Pikalová Z, Zapletalová J, Indrák K. [Therapeutic effectiveness of cladribine and cellular immunodeficiency--related effects in hairy-cell leukemia?]. Vnitr Lek 2002; 48:384-9. [PMID: 12061204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
The high therapeutic efficiency of lymphotoxic purine analogues, pentostatin and cladribine in hairy cell leukaemia which express the antigen CD25 (alpha chain interleukin-2 receptor) suggests the hypothesis whether protracted cellular immunodeficiency after treatment does not represent an important mechanism of control of this specific lymphoproliferation. The authors analyzed a group of 45 patients with CD25-positive hairy cell leukaemia treated with cladribine. In addition to the therapeutic response they evaluated also the state of cellular immunity during the subsequent months and years following cladribine administration. The regression lines of the development of different sub-populations CD4, CD8 and CD56-positive cells, interleukin-2 and its soluble receptor were evaluated separately in patients with persistent remission and patients with growth of the tumourous mass. Although this retrospective analysis provides only limited information we can deduce from it a long-term decline of CD4 lymphocytes correlating with the relatively low incidence of clinical progression of hairy cell leukaemias. The results of this clinical observation are consistent with some reported clinical and experimental observations.
Collapse
Affiliation(s)
- L Raida
- Hemato-onkologická klinika Fakultní nemocnice, Olomouc
| | | | | | | | | |
Collapse
|
42
|
Papajík T, Jedlicková K, Kriegová E, Jarosová M, Raida L, Faber E, Hubácek J, Vondráková J, Pikalová Z, Indrák K. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up. Neoplasma 2002; 48:501-5. [PMID: 11949845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Abstract
The t(14;18) is the most frequent chromosomal aberration observed in follicular lymphoma (FL), and is less frequent in diffuse large cell lymphoma (DLCL). The bcl-2/IgH rearrangement constitutes good target for polymerase chain reaction (PCR) detection that allows to find out one tumor cell in 100,000 normal cells. The PCR assay was used to detect bcl-2-rearranged cells in blood and bone marrow (BM) in 63 previously untreated patients with DLCL and in 53 patients with FL. Twenty five FL patients (47%) and 9 DLCL patients (14%) had PCR-detectable lymphoma cells in BM and peripheral blood. Minimal residual disease (MRD) was evaluated in 17 FL and 5 DLCL patients undergoing first-line chemotherapy. Three DLCL patients (60%) but only 1 FL (6%) patient achieved molecular response (PCR-negative status in BM). Two PCR bcl-2/IgH positive patients with FL were treated with rituximab (anti-CD20 antibody) and had no PCR-detectable lymphoma cells in BM after the therapy. Peripheral blood stem cells (PBSC) were harvested in 5 FL (1 PCR-negative) and in 2 DLCL (1 PCR-negative) patients. PCR-positive lymphoma cells contamined PBSC in all patients with BM PCR-positivity before harvesting. Five FL patients underwent autologous transplantation (AT). No bcl-2/IgH positive cells were detected in 4 patients (80%) at any point after AT. One patient achieved molecular response after rituximab treatment. All the patients are in CR 6, 22, 30, 31 and 42 months respectively, after AT. On the other hand, 4 FL patients in clinical complete remission, but with persistent PCR positivity in BM relapsed with median of 21 months (interval, 14-28 months) from the end of a first-line chemotherapy. Thus, the results show that PCR detection of the bcl-2/IgH rearrangement is a very useful method in evaluating the BM infiltration by lymphoma cells especially in the situation of MRD. Conventional chemotherapy did not eradicate bcl-2 positive cells in BM in most of lymphoma patients, but autologous transplantation or rituximab immunotherapy can induce molecular response in a significant proportion of them. Our results support the previous observations of the molecular response importance in view of better disease free and probably also overall survival.
Collapse
MESH Headings
- Antibodies, Monoclonal/pharmacology
- Antibodies, Monoclonal, Murine-Derived
- Bone Marrow Cells/metabolism
- Bone Marrow Cells/pathology
- Chromosomes, Human, Pair 14/genetics
- Chromosomes, Human, Pair 18/genetics
- Disease-Free Survival
- Follow-Up Studies
- Humans
- Lymphoma, B-Cell/diagnosis
- Lymphoma, B-Cell/drug therapy
- Lymphoma, B-Cell/genetics
- Lymphoma, B-Cell/pathology
- Lymphoma, Follicular/diagnosis
- Lymphoma, Follicular/drug therapy
- Lymphoma, Follicular/genetics
- Lymphoma, Follicular/pathology
- Lymphoma, Large B-Cell, Diffuse/diagnosis
- Lymphoma, Large B-Cell, Diffuse/drug therapy
- Lymphoma, Large B-Cell, Diffuse/genetics
- Lymphoma, Large B-Cell, Diffuse/pathology
- Neoplasm Staging
- Neoplasm, Residual/genetics
- Neoplasm, Residual/pathology
- Polymerase Chain Reaction/methods
- Prognosis
- Proto-Oncogene Proteins c-bcl-2/genetics
- Rituximab
- Survival Rate
- Translocation, Genetic/genetics
Collapse
Affiliation(s)
- T Papajík
- Department of Hemato-oncology, University Hospital, Olomouc, Czech Republic.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Kolar M, Vagnerova I, Latal T, Urbanek K, Typovska H, Hubacek J, Papajik T, Raida L, Faber E. The occurrence of vancomycin-resistant enterococci in hematological patients in relation to antibiotic use. New Microbiol 2002; 25:205-12. [PMID: 12019727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
Very important bacterial pathogens found in hematological patients at present are vancomycin-resistant enterococci (VRE). The main goal of this retrospective study was to assess their occurrence in relation to antibiotic use. We isolated 1918 Enterococcus strains, in toto, 138 (7.2%) of which proved to be VRE. The VRE most frequently identified were Enterococcus faecium VanA (77%) and Enterococcusfaecalis VanB (12%), mostly isolated from stools (57%). Comparing the development of the selection pressure of antibiotics and percentage of VRE in each period of observation, an effect of the administration of each antibiotic group on the occurrence of VRE can be presumed. A reduction in the administration of third generation cephalosporins, glycopeptides and fluoroquinolones and its replacement by penicillin antibiotics combined with inhibitors of bacterial beta-lactamases, contributed to the cessation of VRE incidence and succeeding reduced occurrence from 15.1% in the second half of 1998 to 6.1% in the first half of 2000.
Collapse
Affiliation(s)
- M Kolar
- Department of Microbiology, Faculty of Medicine, Palackỳ University Olomouc, Czech Republic
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Raida L, Papajík T, Hlusí A, Faber E, Urbanová R, Heczko M, Jancíková M, Zapletalová J, Komenda S, Indrák K. [Importance of determination of serum beta-2-microglobulin levels in patients with Hodgkin's lymphoma]. Vnitr Lek 2002; 48:91-5. [PMID: 11949228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Abstract
The authors evaluated retrospectively in a group of 69 adult patients with Hodgkin's lymphoma the relationship between the beta-2-microglobulin serum level, basic demographic parameters (age, sex) and factors characterizing the extent (stage III and IV, "bulk" or mediastinal mass, number of affected areas of lymph nodes) and activity of the tumour (presence of B-symptoms, red cell sedimentation rate, haemoglobin, albumin and lactate dehydrogenase level, number of leucocytes and lymphocytes). They analyzed also the possible prognostic impact of beta-2-microglobulin on the therapeutic response risk of relapse and patient's survival. Methods of univariant statistical analysis confirmed the correlation of beta-2-microglobulin level with all investigated metric parameters of patients (advanced age, number of affected nodes, red cell sedimentation rate and lactate dehydrogenase level, lower albumin, haemoglobin level, numbers of leucocytes and lymphocytes). In multivariant analysis however the only independent metric markers significantly associated with an elevated protein level were more advanced age of the patients (P = 0.0002) and a lower number of leucocytes (P = 0.05). The values of beta-2-microglobulin was not influenced by the extent of the tumour (stage III and IV, "bulk" or mediastinal mass, higher number of affected areas of lymph nodes). Significantly more frequently elevated protein values were recorded in patients with manifestations of B symptoms associated with the diagnosis (P = 0.0003). Multivariant analysis did not prove the importance of the serum level of beta-2-microglobulin as a prognostic factor in the sense of predicted remission, development of a relapse or death in conjunction with progression of Hodgkin's lymphoma.
Collapse
Affiliation(s)
- L Raida
- Hemato-onkologická klinika Fakultní nemocnice, Olomouc
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Jarosová M, Indrák K, Holzerová M, Hubácek J, Faber E, Papajík T, Raida L, Szotkowski T, Knotková R, Hlusí T, Jedlicková K, Pikalová Z, Sulovská I. [Prognostic significance of cytogenetic changes in patients with acute myeloid leukemia (AML). (Analysis of results in 105 patients treated at the Hemato-oncology Clinic of the University Hospital in Olomouc from 1997 to 2000]. Vnitr Lek 2001; 47 Suppl 1:8-14. [PMID: 11693065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
Chromosomal aberrations are one of the most important prognostic factors in patients with acute myeloid leukemia (AML). This work present analysis of conventional cytogenetic results completed by fluorescence in situ hybridization (FISH) obtained from 105 patients in the time of diagnosis of AML. The median age of patients was 51 years (range 19-79 years), with slight predominance of women (female to male ratio 1.2:1). The evaluated group involved all patients with AML diagnosis, treated by intensive induction chemotherapy in the Department of Hematology-oncology, University Hospital, Olomouc during last 4 years with assessable cytogenetic results. Chromosomal changes were found in 63 (60%) patients. The most often affected chromosomes in succession of frequency were 8, 17, 7, 5, 11, 15, 16 a 21. Based on found specific and frequent chromosomal changes the patients were divided into 3 prognostic subgroups and the significance of chromosomal aberrations was evaluated. The subgroup of 17 patients with good prognosis consisted of a patients with acute promyelocytic leukemia with translocation t(15;17), 4 patients with t(8;21) and 4 patients with inv(16). 14 patients of 17 live in complete remission, median of overall survival (OS) is 63 weeks. The subgroup of intermediate prognosis was formed by 60 patients, 42 had normal karyotype and 18 patients had other chromosomal abnormalities. Median OS of this group was 35 weeks. The third subgroup with poor prognosis consisted of 28 patients with changes of chromosomes 3, 5, 7, 11 and complex karyotype. 64.3% of patients received complete remission and median OS was 35 weeks. Statistical evaluation of OS showed significant difference (p = 0.002) in subgroup with good prognosis versus subgroup with poor prognosis and in subgroup with good prognosis versus subgroup with intermediate prognosis (p = 0.014). Statistical significance of OS in subgroup with intermediate prognosis versus subgroup with poor prognosis was not proved (p = 0.34), but fit appeared in evaluation of both groups in patients under 55 years. It seems that in patients in age 55 and more the age is independent poor prognostic factor and findings of chromosomal aberrations do not significantly influence prognosis.
Collapse
Affiliation(s)
- M Jarosová
- Hemato-onkologická klinika FN a LF UP, Olomouc
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Jarosová M, Jedlicková K, Holzerová M, Urbanová R, Papajík T, Raida L, Pikalová Z, Lakomá I, Prekopová I, Kropácková J, Indrák K. Contribution of comparative genomic hybridization and fluorescence in situ hybridization to the detection of chromosomal abnormalities in B-cell chronic lymphocytic leukemia. Onkologie 2001; 24:60-5. [PMID: 11441283 DOI: 10.1159/000050284] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND B-chronic lymphocytic leukemia (B-CLL), the most common type of leukemia in Western Europe and the United States, is characterized by clonal chromosomal abnormalities detected in almost half of the studied patients. The precise determination of chromosomal changes helps to indicate the prognosis and to understand the pathogenesis of CLL. METHODS AND PATIENTS We applied conventional cytogenetics (CC), FISH and comparative genomic hybridization (CGH) to the investigation of clonal abnormalities in 88 B-CLL patients at the time of diagnosis. RESULTS By using CC of bone marrow cells without any stimulation, non-random chromosomal changes were found in 17 (19%) of 88 patients. The employment of FISH and CGH revealed chromosomal changes in additional 33 patients, thus increasing the detection rate of chromosomal abnormalities to 57%. The most common abnormalities detected in our patients included deletions of 13q in 16 cases (18%), followed by trisomy of chromosome 12 in 12 patients (13%), deletions of 11q in 10 patients (11%) and deletions of 17p in 10 patients (11%). A statistically significant correlation between higher disease activity and the presence of deletions 11q and 17p was observed. CONCLUSION The addition of FISH and CGH to CC in 88 B-CLL patients improved the detection of clonal chromosomal changes from 19 to 57%. The most frequent chromosomal change was deletion of 13q14 (18%). Deletions of 11q23 and 17p13 were found in patients with higher clinical disease activity. Our results underline the importance of employing FISH and CGH techniques in CLL patients. CC without any stimulation has a low detection rate and is not suggested for detection of chromosomal changes in CLL.
Collapse
Affiliation(s)
- M Jarosová
- Department of Hematology/Oncology, Palacký University Hospital, Olomouc (Czech Republic).
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Jarosová M, Jedlicková K, Holzerová M, Urbanová R, Papajík T, Raida L, Pikalová Z, Lakomá I, Prekopová I, Kropácková J, Indrák K. [Methods in molecular cytogenetics for determination of prognostically important chromosome changes in patients with chronic lymphatic leukemias]. Cas Lek Cesk 2000; 139:564-9. [PMID: 11109291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
BACKGROUND We applied classical cytogenetics, FISH and CGH to investigate prognostic important chromosomal changes, deletions of 17p, 11q and trisomy of chromosome 12 in 90 B-CLL patients at the time of diagnosis. METHODS AND RESULTS Using classical cytogenetics the chromosomal changes were detected in 17 (18%) patients. Trisomy 12 was found in three patients, deletion 11q in two patients and deletion 17p in four patients. The employment of FISH and CGH revealed chromosomal changes in 52 (58%) patients, the trisomy of chromosome 12 was detected in 12 (13%) patients, the deletions of 11q and deletions of 17p in 10 patients (11%). Statistically significant correlation between higher disease activity and the stage of disease and the presence of deletion 11q and 17p was found. The trisomy of chromosome 12 was found in patients with abnormal markers and in patients with higher stage of the disease. CONCLUSIONS According to our results, the majority of chromosomal abnormalities in B-CLL may escape detection when classical cytogenetics is the only diagnostic technique used. It stresses the importance of employing additional techniques including FISH and CGH at the time of diagnosis.
Collapse
Affiliation(s)
- M Jarosová
- Hemato-onkologická klinika FN a LF, Olomouc
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Raida L. Recent approaches in the treatment of Hodgkin's lymphoma. Acta Univ Palacki Olomuc Fac Med 2000; 142:13-7. [PMID: 10743718] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
An aim has been to find the optimal therapeutic approach for each patient suffering from Hodgkin's lymphoma. The disease with 80% curability rate presents the great success of clinical oncology. There is no doubt that the development and improvement of therapeutic approaches described in this article has contributed to the excellent results achieved in the last twenty years. But a lot of problems still remain to be solved by haemato-oncologists despite such progress in the treatment. The most important tasks are: 1. to increase the curability of advanced stages, 2. to improve therapeutic results in refractory and relapsing patients, 3. to eliminate or decrease the late toxicity particularly in the favourable early and intermediate stages.
Collapse
Affiliation(s)
- L Raida
- Haemato-oncology Department of University Hospital, Olomouc, Czech Republic
| |
Collapse
|
49
|
Papajík T, Raida L, Faber E, Hubácek J, Heczko M, Slezák P, Sulovská I, Pikalová Z, Kynclová E, Dusek J, Tichý M, Jarosová M, Indrák K. [Mantle cell lymphoma as a diagnostic and therapeutic problem]. Vnitr Lek 1999; 45:55-61. [PMID: 10422528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
The authors present the characteristics of a group of 23 patients with mantle cell lymphoma. In the group only a slight predominance of men over women was found (1.1:1), the median age was 63 years. Twenty-one (91%) of the patients were diagnosed in stage IV (Ann Arbor). In all these patients the bone marrow was affected. In 19 of them immunoflowcytometric analysis revealed the typical clone of B lymphocytes (CD5 positive)/CD 23 negative). The majority of patients had at the time of diagnosis a large tumourous mass with massive splenomegaly (61%), hepatomegaly (57%) and bulky disease (52%). The node was excised in 17 patients, but in four patients (24%) during the first session the diagnosis was not assessed correctly. In the laboratory findings an inclination to anaemia, thrombocytopenia, lymphocytosis and in particular to high levels of serological indicators of activity of the disease dominated--lactate dehydrogenase, beta-2-microglobulin and serum thymidine kinase. All patients were treated by chemotherapy. Complete remission was achieved by the date of evaluation in one patient (4%), partial remission in seven patients (30%) but 48% patients did not respond to first line treatment. Nine patients of the group died, their median of survival was 14 months (0-24), the median of the follow up of the remaining patients was 133 months (2-31). Two female patients had large-dose treatment with subsequent administration of autologous stem cells. The first one is after 370 days of treatment in complete remission, the second one developed a relapse 100 days after the procedure. From the results and analysis of the literature ensues that mantle cell lymphoma is one of the aggressive malignant B-lymphoproliferations with a very adverse prognosis and it deserves therefore special diagnostic and intense therapeutic attention.
Collapse
Affiliation(s)
- T Papajík
- Hemato-onkologická klinika FN, Olomouc
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Kolár M, Kurasová Y, Látal T, Hejnar P, Fáber E, Raida L. [Bacterial strains isolated from neutropenic patients and their resistance to antibiotics]. Cas Lek Cesk 1998; 137:84-8. [PMID: 9511277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND Although Gram negative as well as Gram positive bacteria participate in febrile episodes of neutropenic patients, in particular recently the ratio of Gram positive bacteria is increasing. The objective of the present work was to investigate the incidence and antibiotic resistance of pathogenic bacterial agents in neutropenic patients. METHODS AND RESULTS The presence of bacteria was investigated in 446 neutropenic patients hospitalized at the Haematological Clinic in 1995. Haemocultures (apparatus Bact/Alert 120, cultivation media Organon-Teknika) and urine were examined. The sensitivity for antibiotics was tested by the standard dilution micromethod. In blood most frequently Staphylococcus epidermidis was isolated (45.4%), coagulase-negative strains of Staphylococcus haemolyticus, Staphylococcus hominis and Staphylococcus saprophyticus (14.4%), Acinetobacter calcoaceticus-baumannii (complex 6.3%) and Pseudomonas aeruginosa (6.3%). In urine the following were detected: Staphylococcus epidermidis (36.5%), Enterococcus sp. (14.5%), Escherichia coli (13.1%), Enterococcus faecalis (11.6%) and Enterococcus solitarius (6.5%). In all strains resistance to antibiotics and chemotherapeutic drugs was assessed. CONCLUSIONS Investigation of the frequency of different bacterial species, along with monitoring of the resistance is an essential prerequisite of initial antibiotic therapy of febrile episodes in neutropenic patients.
Collapse
Affiliation(s)
- M Kolár
- Ustav lékarské mikrobiologie LF UP, Olomouc
| | | | | | | | | | | |
Collapse
|